Labiotech.eu

News and Trends 23 Mar 2017

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […]

March 23, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 23 Mar 2017

Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics

Located right here in Barcelona, Oryzon is one of the world’s few epigenetics biotechs. I sat down with CEO Carlos Buesa to talk about its approach. Since its foundation in 2000, Oryzon has gone on to become the leader in epigenetic medicine and focuses on oncology. Most recently, the company announced the success of its lead […]

March 23, 2017 - 2 minutesmins - By Evelyn Warner

eppendorf bioflo120 sponsored e1490947196269

News and Trends 23 Mar 2017

Speed up R&D? Eppendorf is Offering a new Solution!

With their latest bioreactor system, BioFlo 120, Eppendorf is aiming to make bioprocesses more flexible and straightforward. Apart from brewing beer, bioprocesses play a major role in the biotech industry. Ever since the breakthrough of genetic engineering technologies in the end of the last century, we have started to exploit microorganisms or mammalian cells as […]

March 23, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 22 Mar 2017

Swedish Oncology Biotech Teams up with World Leading Cancer Center

The Swedish biotech Aprea Therapeutics has entered a new collaboration with the Memorial Sloan Kettering Cancer Center to study the effects of its lead APR-246. Based in Stockholm, Aprea therapeutics is focusing on the development of its only drug candidate, APR-246. The molecule targets the key tumor supressor p53 to restore its function. Now, in collaboration […]

March 22, 2017 - 2 minutesmins - By Melanie De Almeida

Pierre Fabre H Immune research collaboration 3

News and Trends 22 Mar 2017

France’s 2nd Biggest Pharma Enters New Partnership for Immunotherapies

With its new Fund for Innovation, Pierre Fabre will collaborate with H-Immune to use its ‘In Vitro Immunization’ (IVI) platform for the development of fully human monoclonal antibodies (mAbs). Pierre Fabre is the 2nd largest private pharmaceutical company in France and has recently made efforts to open up its innovation process. Since the establishment of the Pierre […]

March 22, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 22 Mar 2017

Watch a Partner at Spain’s Largest VC talk Investment Strategy

At BIO Europe Spring, we met Karen Wagner, a General Partner at Ysios, the VC dominating Spain’s investment scene. She told us what’s on the firm’s radar. Spain’s largest VC has positioned itself in Barcelona, having identified the city’s potential to be the next biotech hub in Europe. It has funded key biotechs in Spain, including Sanifit, which claimed the […]

March 22, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 22 Mar 2017

What’s the Gold Standard for Therapeutic Antibodies?

Are fully human antibodies the new gold standard in therapeutic innovation? If you want to upgrade, here’s where to find them. If you’re curious about the future of antibody development, look no further than Humira. This monoclonal antibody (mAb) for various inflammatory diseases soared to become the best-selling biological in 2016. Humira is a fully human […]

March 22, 2017 - 4 minutesmins - By External Contributor

News and Trends 21 Mar 2017

A Potential First Treatment for a Rare Genetic Disease clears Phase I

Minoryx Therapeutics has successfully completed a Phase I trial for its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD). The Spanish biotech Minoryx is specialized on orphan diseases and its lead program is a PPAR-gamma agonist, MIN-102, which is in development for X-ALD. The company now announced the successful results of its Phase I trial with MIN-102 revealing the […]

March 21, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 21 Mar 2017

Better than Quantum Computing: The EU Launches a Biocomputer Project

The EU Horizon 2020 has launched Bio4Comp, a five-year €6.1M project to build more powerful and safer biocomputers that could outperform quantum computing. The Bio4Comp project has the ambitious goal of building a computer with greater processing speed and lower energy consumption than any of the most advanced computers existing today. Ultimately, this could translate into […]

March 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 21 Mar 2017

Rethinking Profits: Can a Socially Conscious Model work in Biotech?

As biopharma continues to weather a maelstrom of public scrutiny for its prices and profits, I asked executives about alternative models. Conventional wisdom in biotech is that the non-profit model can’t work in the industry: it takes a decade and billions in cash to develop a drug, with no guaranteed success. No investor would sink […]

March 21, 2017 - 7 minutesmins - By Evelyn Warner

C7XeJ78WkAEE Ic 1.jpg large e1490029653662

Interview 20 Mar 2017

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

The unprecedented competition in the field represents a daunting challenge for companies trying to break in. A BIO-Europe Panel discussed remaining niches. BIO Europe’s panel on immuno-oncology was perhaps the most popular of the day, as attendees filled the room to hear the thoughts of John Haurum, CEO of F-star; Christophe Quéva, CSO of iTeos; and […]

March 20, 2017 - 3 minutesmins - By Evelyn Warner

Galecto Biotech BMS TD139 Phase Ia IIb 1

News and Trends 20 Mar 2017

Will BMS Take Over a Danish Biotech in a Massive €400M Deal?

Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option of take over the biotech. In 2014, Denmark’s Galecto Biotech has signed an option agreement with US-based pharma Bristol-Myers Squibb (BMS) for its lead asset TD139, which is under development for the treatment of pulmonary […]

March 20, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics

Speed up R&D? Eppendorf is Offering a new Solution!

Swedish Oncology Biotech Teams up with World Leading Cancer Center

France’s 2nd Biggest Pharma Enters New Partnership for Immunotherapies

Watch a Partner at Spain’s Largest VC talk Investment Strategy

What’s the Gold Standard for Therapeutic Antibodies?

A Potential First Treatment for a Rare Genetic Disease clears Phase I

Better than Quantum Computing: The EU Launches a Biocomputer Project

Rethinking Profits: Can a Socially Conscious Model work in Biotech?

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

Will BMS Take Over a Danish Biotech in a Massive €400M Deal?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!